|
rs1800795
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Simultaneously, rs1800795 and rs1800796 were associated with a significantly higher risk of cancer in Asia and Caucasian, rs1800797 was associated with a significantly risk of cancer in Caucasian but not in Asia.
|
29552316 |
2018 |
|
rs1800795
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We observed a non-significant association between rs1800795 and overall cancer risk, while rs1800797 was found to have a false positive association with overall risk of cancer.
|
29842912 |
2018 |
|
rs1800795
|
|
|
0.040 |
GeneticVariation |
BEFREE |
To date, several association studies examining rs1800795 allele frequency and disease risk have reported seemingly conflicting results ranging from no association to association with either the major or minor allele across a spectrum of conditions, including cancer and autoimmune, cardiovascular, infectious, and metabolic diseases.
|
26578807 |
2015 |
|
rs1800795
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) cancer.
|
17694420 |
2007 |
|
rs1800796
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Considering these promising results, IL-6 promoter including rs1800795, rs1800796 and rs1800797 may be a tumor marker for cancer therapy.
|
29552316 |
2018 |
|
rs1800796
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our study demonstrates that rs1800796 is significantly associated with cancer risk in three genetic models (allele G vs allele C, pooled OR = 1.182, P = 0.009; CG + GG vs CC, pooled OR = 1.333, P = 0.006; CG vs CC, pooled OR = 1.323, P = 0.007).Our meta-analysis suggests that polymorphism rs1800796 within the IL6 gene may be a potential risk factor for cancer.
|
26535637 |
2015 |
|
rs1800796
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) cancer.
|
17694420 |
2007 |
|
rs1800797
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Considering these promising results, IL-6 promoter including rs1800795, rs1800796 and rs1800797</span> may be a tumor marker for cancer therapy.
|
29552316 |
2018 |
|
rs1800797
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We observed a non-significant association between rs1800795 and overall cancer risk, while rs1800797 was found to have a false positive association with overall risk of cancer.
|
29842912 |
2018 |
|
rs2069837
|
|
|
0.010 |
GeneticVariation |
BEFREE |
IL6 rs2069837 genotype is a clinically relevant prognostic factor in mCRC patients treated with first-line bevacizumab-based chemotherapy.Clin Cancer Res; 22(13); 3218-26.©2016 AACR.
|
26839145 |
2016 |